Chris Martin, IASLC Media Relations | [email protected] | 630.670.2745
What: The International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer Press Briefing featuring abstracts from the Presidential Symposium
When: September 9 2021, 9 a.m.GMT/10 a.m. CDT/11 a.m. EDT
About: Each IASLC World Conference on Lung Cancer highlights the best in lung cancer research. Like the previous two meetings, this conference will be virtual. Each press briefing will be moderated by an IASLC member and include an IASLC Patient Research Advocate, to provide a unique perspective on how research may affect patients coping with lung cancer.
Zoom link: https://us02web.zoom.us/j/88304099531
Moderator: Paul E. Van Schil, MD, PhD
Melissa L. Johnson, MD
PL02.01: Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the Phase 3 POSEIDON study
Luis Paz-Ares, MD, PhD
PL02.03: Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: Phase III randomized ATLANTIS trial
Nasser K. Altorki, MD
PL02.05: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
Christine D. Berg, MD
PL02.07: Global variability in lung cancer deaths attributable to air pollution
Matthew Smeltzer, PhD, MS
PL02.09: International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
Upal Basu Roy, PhD, MS, MPH
Patient Research Advocate
- Press briefings will be conducted via Zoom and recordings will be sent after the briefing concludes.
- Embargoes: abstracts that are part of the press program will be embargoed for beginning of each day’s press briefing. The IASLC reserves the right to change an embargo to account for a journal publication or other issues.
- Media Registration: If you have not registered to cover the meeting, visit https://wclc2021.iaslc.org/.